Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
All olokizumab studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchOlokizumabOlokizumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   All Outcomes       

An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

Samsonov et al., NCT04380519, NCT04380519
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -50% Improvement Relative Risk Improvement 2+ points 30% Improvement 1+ points 30% Olokizumab  Samsonov et al.  LATE TREATMENT  DB RCT Is late treatment with olokizumab beneficial for COVID-19? Double-blind RCT 372 patients in Russia Higher mortality (p=0.6) and greater improvement (p=0.21), not sig. c19early.org Samsonov et al., NCT04380519, January 2022 Favorsolokizumab Favorscontrol 0 0.5 1 1.5 2+
RCT 248 hospitalized patients showing no significant differences with olokuzimab.
Important missing comments or errors? Let us know.
Study covers olokizumab and goflikicept.
risk of death, 50.0% higher, RR 1.50, p = 0.60, treatment 9 of 124 (7.3%), control 6 of 124 (4.8%), day 29.
risk of no improvement 2+ points, 30.0% lower, RR 0.70, p = 0.21, treatment 21 of 124 (16.9%), control 30 of 124 (24.2%), NNT 14, day 29.
risk of no improvement 1+ points, 29.7% lower, RR 0.70, p = 0.14, treatment 26 of 124 (21.0%), control 37 of 124 (29.8%), NNT 11, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Samsonov et al., 24 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Russia, preprint, 1 author, trial NCT04380519 (history). Contact: sa.grishin@rpharm.ru.
This PaperOlokizumabAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0